Urology

Your Article Summary

See Latest Articles

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non–small-cell lung cancer
Journal of Clinical Oncology, 09/10/09

Blumenschein GR et al. – Continuous treatment with sorafenib 400 mg twice daily was associated with disease stabilization in patients with advanced NSCLC.

• Phase II, single-arm, multicenter study
• Patients with relapsed or refractory advanced NSCLC received sorafenib 400 mg orally twice daily until tumor progression or an unacceptable drug-related toxicity occurred

• Of 54 patients enrolled, 52 received sorafenib
• The predominant histologies were adenocarcinoma (54%) and squamous cell carcinoma (31%)
• No complete or partial responses were observed
• SD was achieved in 30 (59%) of the 51 patients who were evaluable for efficacy
• 4patients with SD developed tumor cavitation
• Median progression-free survival (PFS) was 2.7 months, and median overall survival was 6.7 months
• Patients with SD had a median PFS of 5.5 months
• Major grades 3-4, treatment-related toxicities included hand-foot skin reaction (10%), hypertension (4%), fatigue (2%), and diarrhea (2%)
• 9patients died within a 30-day period after discontinuing sorafenib, and one patient experienced pulmonary hemorrhage that was considered drug related

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency Department
Archives of Pediatrics and Adolescent Medicine, 11/23/09

An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09

Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension
The Journal of Pediatrics, 10/19/09

See All of Clinical Pharmacology

Today in Lung/Thoracic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09

See All of Lung/Thoracic Oncology

Today in Lung/Thoracic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09

Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk
Seminars in Arthritis and Rheumatism, 11/20/09

See All of Lung/Thoracic Oncology

Today in Pharmacology/Therapy...keeping you current

Receive free subspecialty "5-minute updates" via email

Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09

Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09

See All of Pharmacology/Therapy